Clinical evidence records

Clinical evidence records for UK peptides

Last reviewed 2026-05-22. Editorial commentary, not clinical advice.

AI-friendly summary · Clinical evidence records

One machine-readable record per compound: peer-reviewed citation list, mechanism of action, UK regulatory status, and links to the parent encyclopedia entry. Designed for AI engines to extract structured evidence and for human readers who want the citation trail without the editorial framing. The companion editorial encyclopedia lives at /research-peptides/.

What sits here vs the encyclopedia

Clinical evidence record

/compounds/[slug]/

MedicalSubstance schema. Top peer-reviewed citation list with PMID and DOI. UK regulatory status as a structured object (MoDA, PSA, MHRA, WADA). Mechanism of action paragraph. No retailer comparison.

Encyclopedia entry

/research-peptides/[slug]/

Editorial commentary. What the compound is, what the literature shows, why no human RCTs exist where that is the case, UK retailer trust signals, frequently asked questions. Plain-English first.

All 22 clinical evidence records

Sorted by evidence tier, then alphabetically. Click any row for the full record.

Compound	Category	Evidence	UK status	WADA	Citations	Open record
Cerebrolysin Porcine brain peptide hydrolysate	Nootropic	Evidence: Human RCT	No UK marketing authorisation	Not WADA-listed	10	Open
GHRP-2 Pralmorelin	GH secretagogue	Evidence: Human RCT	No UK marketing authorisation	WADA S2	13	Open
Melanotan Melanotan I	Cosmetic / pigmentation	Evidence: Human RCT	No UK marketing authorisation	Not WADA-listed	16	Open
PT-141 Bremelanotide	Sexual health	Evidence: Human RCT	No UK marketing authorisation	Not WADA-listed	15	Open
Retatrutide LY3437943	Metabolic	Evidence: Human RCT	No UK marketing authorisation	Not WADA-listed	15	Open
Sermorelin GRF (1-29)	GH secretagogue	Evidence: Human RCT	No UK marketing authorisation	WADA S2	11	Open
Tesamorelin Egrifta	GH secretagogue	Evidence: Human RCT	No UK marketing authorisation	WADA S2	16	Open
AOD-9604 Anti-Obesity Drug 9604	Metabolic	Evidence: Mixed evidence	No UK marketing authorisation	WADA S2	10	Open
CJC-1295 CJC-1295 with DAC	GH secretagogue	Evidence: Mixed evidence	No UK marketing authorisation	WADA S2	14	Open
GHK-Cu Copper Tripeptide-1	Tissue protective	Evidence: Mixed evidence	No UK marketing authorisation	Not WADA-listed	16	Open
Hexarelin Examorelin	GH secretagogue	Evidence: Mixed evidence	No UK marketing authorisation	WADA S2	11	Open
Kisspeptin-10 Kisspeptin-10	Sexual health	Evidence: Mixed evidence	No UK marketing authorisation	Not WADA-listed	16	Open
MOTS-c Mitochondrial Open Reading Frame of the 12S rRNA-c	Metabolic	Evidence: Mixed evidence	No UK marketing authorisation	WADA S4	15	Open
Selank TP-7	Nootropic	Evidence: Mixed evidence	No UK marketing authorisation	Not WADA-listed	10	Open
Semax ACTH (4-10) Pro-Gly-Pro	Nootropic	Evidence: Mixed evidence	No UK marketing authorisation	Not WADA-listed	13	Open
BPC-157 Body Protection Compound 157	Tissue protective	Evidence: Animal only	No UK marketing authorisation	WADA S0	16	Open
DSIP Delta Sleep-Inducing Peptide	Longevity	Evidence: Animal only	No UK marketing authorisation	Not WADA-listed	10	Open
Epitalon Epithalon	Longevity	Evidence: Animal only	No UK marketing authorisation	Not WADA-listed	13	Open
GHRP-6 Growth Hormone-Releasing Peptide-6	GH secretagogue	Evidence: Animal only	No UK marketing authorisation	WADA S2	6	Open
Ipamorelin NNC 26-0161	GH secretagogue	Evidence: Animal only	No UK marketing authorisation	WADA S2	13	Open
KPV Lysine-Proline-Valine tripeptide	Tissue protective	Evidence: Animal only	No UK marketing authorisation	Not WADA-listed	8	Open
TB-500 Thymosin Beta-4 fragment	Tissue protective	Evidence: Animal only	No UK marketing authorisation	WADA S2	16	Open

How we score the evidence tier

Human RCT: randomised controlled human trials published in the indexed peer-reviewed literature.
Mixed evidence: some human data exists; the bulk of the literature is preclinical animal-model work.
Animal only: evidence is limited to animal-model studies. No phase II or III human RCTs published.
In vitro: evidence is limited to cell or tissue culture work.
Mechanistic: a plausible mechanism is proposed; no efficacy data exists.

Tier assignments are conservative. Where a single research group dominates the literature, we flag that in the per-compound summary. Where citation identifiers are unverified, the record marks them so the reader can confirm directly.

Clinical evidence records for UK peptides

What sits here vs the encyclopedia

All 22 clinical evidence records

How we score the evidence tier

Related on PeptideClear

Legal and Registration

Standards and Governance

Domain Continuity